Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Fasting hyperglycemia contributes disproportionately to nonenzymatic glycosylation and the microvascular complications of type 2 diabetes. However, little is known about the regulation of glucose concentrations in the fasting state relative to what is known about the postprandial state. The proposed experiment is part of a series of experiments designed to establish how glucagon and insulin interact with their receptors to control fasting glucose in health and in prediabetes.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 25
Maximum Age: 65
Healthy Volunteers: t
View:
• Individuals with normal or impaired fasting glucose and normal or impaired glucose tolerance
Locations
United States
Minnesota
Mayo Clinic in Rochester
RECRUITING
Rochester
Contact Information
Primary
Kim Osmundson, CCRP
Osmundson.Kimberly@mayo.edu
507-255-0907
Backup
Jeanette Laugen
Laugen.Jeanette@mayo.edu
507-255-8110
Time Frame
Start Date: 2025-04-01
Estimated Completion Date: 2027-07-01
Participants
Target number of participants: 60
Treatments
Active_comparator: Glucagon Infusion
A glucagon infusion (0.2 ng/kg/min) will start at 0900 (0 min), increasing to 0.4 (1000), 0.6 (1100) and 0.8 ng/kg/min (1200) at 60-minute intervals - ending at 1300 (240 min).
Placebo_comparator: Glucose Infusion
At 0900 (0 min) a glucose infusion will commence, and the infusion rate varied to replicate (± 5mg/dL) that individual's glucose concentrations observed during the Glucagon Infusion Day. The experiment will end at 1300 (240 min) when infusions are stopped.
Related Therapeutic Areas
Sponsors
Leads: Mayo Clinic